tiprankstipranks
Trending News
More News >
Charmacy Pharmaceutical Co., Ltd. Class H (HK:2289)
:2289
Hong Kong Market

Charmacy Pharmaceutical Co., Ltd. Class H (2289) Financial Statements

Compare
0 Followers

Charmacy Pharmaceutical Co., Ltd. Class H Financial Overview

Charmacy Pharmaceutical Co., Ltd. Class H's market cap is currently HK$756.00M. The company's EPS TTM is HK$0.266; its P/E ratio is 13.09; and it has a dividend yield of 6.99%. Charmacy Pharmaceutical Co., Ltd. Class H is scheduled to report earnings on March 28, 2025, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue¥ 4.44B¥ 4.40B¥ 4.18B¥ 3.79B¥ 3.99B
Gross Profit¥ 324.76M¥ 292.74M¥ 268.61M¥ 234.12M¥ 237.40M
Operating Income¥ 73.25M¥ 66.19M¥ 93.49M¥ 74.42M¥ 88.08M
EBITDA¥ 166.95M¥ 136.92M¥ 119.19M¥ 107.55M¥ 111.03M
Net Income¥ 53.28M¥ 51.34M¥ 90.47M¥ 23.15M¥ 40.56M
Balance Sheet
Cash & Short-Term Investments¥ 563.15M¥ 644.76M¥ 503.81M¥ 641.76M¥ 602.02M
Total Assets¥ 3.46B¥ 3.25B¥ 2.87B¥ 2.76B¥ 2.80B
Total Debt¥ 1.70B¥ 1.56B¥ 1.41B¥ 1.61B¥ 1.64B
Net Debt¥ 1.13B¥ 927.26M¥ 913.11M¥ 981.75M¥ 1.05B
Total Liabilities¥ 2.84B¥ 2.65B¥ 2.27B¥ 2.26B¥ 2.30B
Stockholders' Equity¥ 618.69M¥ 597.81M¥ 594.48M¥ 504.10M¥ 502.55M
Cash Flow
Free Cash Flow¥ 90.31M-¥ 35.46M¥ -44.58M¥ 79.10M
Operating Cash Flow¥ 106.04M-¥ 44.05M¥ -19.54M¥ 131.08M
Investing Cash Flow-¥ 39.34M¥ 71.76M¥ -24.40M¥ -54.78M
Financing Cash Flow-¥ 101.26M¥ -191.21M¥ 74.40M¥ -2.68M
Currency in CNY

Charmacy Pharmaceutical Co., Ltd. Class H Earnings and Revenue History

Charmacy Pharmaceutical Co., Ltd. Class H Debt to Assets

Charmacy Pharmaceutical Co., Ltd. Class H Cash Flow

Charmacy Pharmaceutical Co., Ltd. Class H Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis